KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 0.19.

  • Teva Pharmaceutical Industries' Equity Ratio rose 4196.69% to 0.19 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.19, marking a year-over-year increase of 4196.69%. This contributed to the annual value of 0.19 for FY2025, which is 4196.69% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Equity Ratio is 0.19, which was up 4196.69% from 0.18 recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Equity Ratio peaked at 0.24 during Q3 2021, and registered a low of 0.14 during Q4 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' Equity Ratio had a median value of 0.19 in 2025 and averaged 0.19.
  • In the last 5 years, Teva Pharmaceutical Industries' Equity Ratio crashed by 2680.1% in 2024 and then soared by 4196.69% in 2025.
  • Teva Pharmaceutical Industries' Equity Ratio (Quarter) stood at 0.24 in 2021, then decreased by 17.18% to 0.2 in 2022, then dropped by 4.33% to 0.19 in 2023, then dropped by 26.8% to 0.14 in 2024, then skyrocketed by 41.97% to 0.19 in 2025.
  • Its Equity Ratio was 0.19 in Q4 2025, compared to 0.18 in Q3 2025 and 0.17 in Q2 2025.